Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cerevance Inc. has 1 pending office action currently active in the Biotechnology & Pharmaceuticals technology area. This matter is being handled by 1 distinct examiner, indicating a singular point of contact for the company's current patent prosecution. The use of 1 distinct art unit suggests the technology being patented is highly specialized within the pharmaceutical sector. This concentration limits the complexity of managing multiple examiner preferences or art unit standards.
The busiest examiner for this portfolio is HABTE, KAHSAY, who is managing 1 busiest examiner pending action. Since there is only 1 pending office action in total, HABTE, KAHSAY is responsible for the company's entire active docket. The ratio of pending actions to examiners means that the prosecution outcome is entirely dependent on this individual's review. This 1 distinct examiner operates within the 1 distinct art unit assigned to the case.
For a company in the Biotechnology & Pharmaceuticals field, having 1 pending office action represents a very focused stage of intellectual property development. The 1 busiest examiner pending action is the only current hurdle to overcome in this technology area. Practitioners should focus on the specific requirements of the assigned examiner, as this individual holds the key to the company's current patent goals. The lack of additional pending actions simplifies the overall prosecution landscape.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275862 | NOVEL COMPOUNDS | HABTE, KAHSAY | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275862 | NOVEL COMPOUNDS | HABTE, KAHSAY | 1624 | §102§112 | Non-Final OA | — | Pending | Aug 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCerevance Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kahsay Habte has the most, with 1 of Cerevance Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
